P/E ratio for Medpace (MEDP)
P/E ratio as of April 2024 (TTM): 44.6
According to Medpace's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 44.6215. At the end of 2022 the company had a P/E ratio of 27.9.
P/E ratio history for Medpace from 2016 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 27.9 | -35.02% |
| 2021 | 43.0 | 25.76% |
| 2020 | 34.2 | 13.52% |
| 2019 | 30.1 | 16.69% |
| 2018 | 25.8 | -28.79% |
| 2017 | 36.3 | -64.65% |
| 2016 | 103 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 ORIC Pharmaceuticals
ORIC | -3.70 | -108.30% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.